Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis

Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM). We herein report a case of a 34-year-old woman with LAM who developed refractory chylothorax and chylous ascites during sirolimus therapy. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Namba, Masashi, Masuda, Takeshi, Nakamura, Takashi, Horimasu, Yasushi, Miyamoto, Shintaro, Nakashima, Taku, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790722/
https://www.ncbi.nlm.nih.gov/pubmed/29021448
http://dx.doi.org/10.2169/internalmedicine.8645-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790722/
https://www.ncbi.nlm.nih.gov/pubmed/29021448
http://dx.doi.org/10.2169/internalmedicine.8645-16

Ejemplares similares